Monday, November 23, 2009

Watch List for Monday - CVSL !!!

CVSL hasn't traded much in the past because no one knows about the company, this also makes it a very unique opportunity so make sure it's on your watch list!!

Since CVSL is still small right now and holds the patent for a product that makes critical procedure easier, could CVSL possibly become a buy out candidate one day? Unusually the large companies will come in and buy out these small companies before they can get big.

Read this article about how one man started two different eye companies and sold them both one for $300 Mill. http://www.nytimes.com/2008/05/15/business/smallbusiness/15edge.html

The medical device industry is a huge one. They are usually dominated by a few huge players like Allergan which makes the lap-band, botox and other implants. Allergan trades at around $58 a share. Then there's Edwards Life Science that provides products and technologies for heart valve therapy, critical care, cardiac surgery systems, and vascular disease. It trades at around $81 a share.

CVSL currently only has one major product but this is a very important product.

CVSL has the US patent for an innovative next-generation "steerable guidewire" applicable for all angioplasty procedures. The guidewire has a unique opportunity to become the guidewire of choice for surgeons throughout the world.

The technology hinges on a bendable tip that improves guidewire performance, enables faster procedure completion, and provides cost benefits for patients as well as healthcare providers.

CVSL just announced they are to apply for additional patents in Europe, Canada and the Far East.

Angioplasty is a common procedure that is performed to widen narrowed or obstructed blood vessels. The procedure is often performed in place of, or before a more invasive and potentially life-threatening bypass surgery is needed. Angioplasty that is performed before an artery is fully-blocked can prevent the onset of heart attacks.

More than seven million angioplasties are performed worldwide each year. The potential addressable market for angioplasty equipment exceeds $500 million.

According to the World Health Organization, some 7.2 million men and women die as a result of cardiac heart disease. Heart disease is the leading cause of death for both women and men in the United States.

Do your own research and consult with your own financial professional. Start your research at: http://www.cvslmedical.com

No comments: